Vivek Subbiah: “Bringing the Best Minds Together to Tackle Cancer” at the United Nations General Assembly

Vivek Subbiah shared a post on LinkedIn:

“I was deeply honored and excited to have spoken at the United Nations event during the United Nations General Assembly on September 25th, 2024, in a pivotal session titled  ‘Bringing the Best Minds Together to Tackle Cancer.’ This event represented a significant step forward in our collective effort to combat one of the most challenging health issues of our time.

United Nations Headquarters, New York, NY 10017, USA

Cancer is a global challenge that transcends borders and affects us all. However, through innovation and collaboration, we made remarkable strides in prevention, early detection, diagnostics, and treatment.

This session brought together pioneering teams and the sharpest minds from around the world to discuss and implement innovative approaches like Precision Oncology that can bridge the inequalities in access to cancer care.

Special thanks to the amazing Denis Horgan, Executive Director, Chair, ICGC ARGO Independent Advisory Committee, International Cancer Genome Consortium, and Donal Cronin from the Permanent Mission of Ireland to the United Nations, International Cancer Patient Coalition and European Alliance for Personalised Medicine (EAPM) for the invite.

I am thankful to the incredible multi-stakeholder cancer care advocates representing many nations who were there. Denis Horgan, Ph.D

I invite everyone to join in mobilizing the collective power of international collaboration to drive meaningful change and support the global fight against cancer. Together, we can make a significant difference and strive for a future where cancer is no longer a threat to global health.

Let’s continue to unite, innovate, and inspire action.”

Source: Vivek Subbiah/LinkedIn

More posts featuring Vivek Subbiah on oncodaily.com

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.